Abingworth Management, Inc.

3000 Sand Hill Road Bldg. 4, Suite 135

Menlo Park, CA 94025

1 650 926 0600

www.abingworth.com

Abstract Description

Investment firm dedicated to the life sciences sector in the United States and abroad.

Management

Stephen Bunting- Managing Partner Victoria Stewart- Principal, Public Relations David Leathers- Partner Alex Asquith- Assistant Counsel

Keywords

Therapeutics, Vaccines, Diagnostics, Medical devices, Platform technologies.

Comment | Printable Version | 1 of 1 | |

//

Description

Abingworth is an investment firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Abingworth has provided backing for more than 100 unquoted life science businesses.

Customers/Clients

Avila Therapeutics Dicerna Pharmaceuticals Hydra Biosciences Intellikine Kspine Pathwork Diagnostics Primera Biosystems Stanmore Implants Valeritas Ablynx Alexza Molecular Delivery Corporation Broncus Technologies Dynogen Pharmaceuticals Fovea Gynesonics Healthcare Brands International (HBI) Intelligent Medical Implants Magellan Biosciences Novexel Portola Pharmaceuticals PowderMed Prosensa Therapeutics Supernus Pharmaceuticals Synosia Therapeutics Syntaxin Zogenix Akubio Alnylam Pharmaceuticals Astex Therapeutics BioImage Chroma Therapeutics Galï¿½pagos NV Guava Technologies Hydra Biosciences Inpharmatica Labcyte Lorantis ParAllele BioScience Solexa XCounter Xenogen Corporation Adiana ArgoMed Astex Therapeutics Clinical Designs Devgen Entelos Epigenomics Healtheon Iconix Pharmaceuticals Lorantis Micromet Oxagen Pharmion Protein Mechanics Sensors for Medicine and Science Solexa Sunesis Pharmaceuticals Allos Therapeutics Aurora Biosciences Aviron GelTex Pharmaceuticals GeneMedicine Hexagen Neurocrine Biosciences Pharmacopeia Versicor Alkermes Cantab Pharmaceuticals Dura Pharmaceuticals Genetic Therapy GenPharm Gilead Sciences IDEC Pharmaceuticals Interventional Technologies Molecular Dynamics Neurogen

Strategy/Focus

In addition to private company investments, Abingworth aims to invest in undervalued public companies that have the potential to provide venture capital-like returns. The company uses its networks, financial expertise and industry knowledge to select firms with experienced management and products or technology with significant commercial potential.

2012-05-24-1485 SELECT * FROM `master` WHERE CompanyID='10450' AND `Profile_Type` LIKE 'resource' AND `Approved` LIKE 'YES' ORDER BY `Member_Priority` ASC LIMIT 0 , 30